Morepen Laboratories Limited (MOREPENLAB)
Small CapPharma stocks · Small cap · NSE
Morepen Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +34% YoY · PAT +409% YoY · margin expansion · +18% QoQ · operating leverage
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹570 Cr | +34.1% | +17.5% |
| EBITDA | ₹83 Cr | +245.8% | +245.8% |
| Operating margin | 14.0% | +800 bps | +900 bps |
| PAT | ₹56 Cr | +409.1% | +250.0% |
| PAT margin | 9.8% | +723 bps | +652 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Issuer presentation review pending
Morepen Laboratories Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
Trend score and candlestick chart
71Bullishfull bull SMA stack · SMA20 +54.6% / mo · RSI overbought · MACD + · near 52W high · sector +2.2pp vs Nifty (3M)
Technical chart
MOREPENLABdaily · 1Y · AUTO+178.6%Daily technical trend read
Bullish setupTrend is constructive — long-term uptrend intact. RSI 75.
- Price > SMA20 > SMA50 > SMA200 — full bullish stack.
- SMA20 rising (~35.3% over last month) — short-term momentum positive.
- RSI(14) at 75 — overbought zone; risk of mean reversion.
- MACD above signal, histogram expanding — bullish momentum building.
- 4% off 52W high · 244% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 20 · OVERVALUED · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 20 · OVERVALUED · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
OVERVALUEDWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 8/15 to the score.
- Cash flow contributes 4/10 to the score.
Main drags
- Penalty bucket subtracts 1 points.
- Fair-value margin of safety is negative at -762.8%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 63rd percentile of the scored universe and 50th percentile within Pharma. Main check: financial discipline is weak at 42/100.
Healthy Trust Lite: Promoter pledge is zero. Key concern: ROE is low at 6.2%.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 50th pctile, median 70 · Small: 66th pctile, median 66
103 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter pledge is zero.
- ▸5 years of positive FCF.
- ▸3/4 latest quarters had positive YoY revenue growth.
- ▸3/4 latest quarters had positive YoY PAT growth.
Trust risks
- ▸ROE is low at 6.2%.
- ▸ROCE trend is -5.3%.
- ▸2 older quarters in the 8-quarter window had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 53.10
- P/B
- 5.00
- EV/EBITDA
- 29.27
- Market Cap
- 6232.00Cr
Profitability
- ROE
- 6.20%
- ROCE
- 8.05%
- ROA
- 7.93%
- Dividend Y
- 0.18%
Growth (CAGR)
- Revenue 5Y
- 9.00%
- EPS 5Y
- -5.00%
- Revenue 3Y
- 8.00%
- EPS 3Y
- 24.00%
Balance Sheet
- Debt/Equity
- 0.17
- Interest Coverage
- 10.82×
- Altman Z
- 8.51
- Book Value
- 22.80
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 5/5
- OCF
- 33.00 Cr
- EPS TTM
- 2.57
Shareholding
- Promoter Hold
- 35.66%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 94%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.